Free Webinar
Register today—space is limited.

AUA Prostate Cancer Webinar:
Advances in Radiation Therapy for Localized Prostate Cancer
Michael J. Zelefsky, M.D.
Chief Brachytherapy Service
Memorial Sloan-Kettering Cancer Center
New York, NY

June 25, 2008, 8:00 p.m. EDT

Description/Purpose/Need
The American Urological Association (AUA) is proud to offer a FREE Prostate Cancer Webinar Series on many topics related to the treatment of prostate cancer, presented by expert faculty from around the country. The AUA is proud to offer a the first of a series of FREE Prostate Cancer Webinars on many topics related to the treatment of prostate cancer, presented by expert faculty from around the country. This is an opportunity to gain 0.5 AMA PRA Category 1 Credits™ for each webinar you view without leaving your home or office.

During the last 10 years there have been significant advancements in radiotherapy for prostate cancer which have directly improved outcomes and effectively reduced long-term treatment related toxicities. Randomized trials have now established that improved survival outcomes can be achieved for locally advanced disease with combined androgen deprivation and external beam radiotherapy. Similar phase III studies have now demonstrated the importance of using escalated radiation dose levels to achieve optimal tumor control outcomes. New technologies such as intensity modulated radiotherapy and image-guided radiation therapy has resulted in enhanced precision to target necessary high doses to the prostate and achieving concomitant reduction of dose to surrounding normal structures leading to reduced long-term complications. Similar improvements have been made for prostate brachytherapy (low-dose rate and high-dose rate treatments) in the form of real-time conformal treatment planning and image-guided approaches which continue to improve the accuracy of seed placement and lead to greater reduction of treatment-related morbidities.

Attendance is limited for the live program. 30-minute program with a 15-minute question-and-answer period following the presentation. Program will also be available on-line the day after the live event.

Target Audience
This program is designed for all who treat prostate cancer, primarily urologists and radiation oncologists, with additional interest during September for internists, family practice and allied health professionals.

Learning Objectives
After completing this module, the participant will be able to:

1. Describe the indications for combined androgen deprivation therapy and radiotherapy for patients with locally advanced disease.
2. Discuss the role of dose escalation for patients with localized prostate cancer.
3. Summarize the importance of intensity modulated radiation therapy (IMRT) and image-guided radiotherapy (IGRT) for enhancing the conformality of radiation dose delivery and the observed reduction of treatment-related side-effects.
4. Identify the recent technological enhancements in LDR and HDR prostate brachytherapy and the role these treatments play in the management of clinically localized disease and salvage therapies

Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AUA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit Designation
The American Urological Association designates this educational series for a maximum of 5.5 AMA PRA Category 1 Credits™ or each webinar activity for 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AUA Disclosure Policy
As a provider accredited by the ACCME, the AUA must insure balance, independence, objectivity and scientific rigor in all its activities.

All faculty participating in an educational activity provided by the AUA are required to disclose to the audience any relevant financial relationships with any commercial interest to the provider. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments. The AUA must resolve any conflicts of interest prior to the commencement of the educational activity. It remains for the audience to determine if the faculty's relationships may influence the educational content with regard to exposition or conclusion. When unlabeled or unapproved uses are discussed, these are also indicated.

Unlabeled or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses or drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Evidence-based Content
As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.